LIXTE Biotechnology Pivots to AI Energy Infrastructure, Appoints Denham Capital Founder to Board

LIXTE Biotechnology Holdings is exiting pharmaceutical development and repositioning as an AI energy infrastructure equipment and services platform, a structural shift that will redirect the company's clinical-stage oncology and med-tech pipeline toward a strategic acquisition partner while its Nasdaq listing under LIXT remains intact.

The pivot is framed against a documented supply gap. In its January 2026 Long-Term Reliability Assessment, the North American Electric Reliability Corporation (NERC) projected summer peak demand will increase by 224 gigawatts over the next decade, with several major grid regions flagged for elevated supply-shortfall risk. In April 2026, NERC issued a rare Level 3 Alert directing grid operators to address reliability risks tied to large-scale computational loads — the same load profile LIXTE is now targeting commercially.

Stuart D. Porter, founder, managing partner, CEO and CIO of Denham Capital Management LP, joins the board effective June 1, 2026. Porter founded Denham Capital in 2004 and has overseen more than $12 billion of invested and committed capital across energy and energy-transition sectors. Denham Capital's infrastructure group is currently advancing a U.S. and European pipeline of approximately 10 GW of AI data-center-oriented power generation assets, drawing on execution experience across gas, renewable, and storage projects globally.

LIXTE's stated strategy targets three operational areas: power equipment and services for hyperscale AI and data-center campuses, including long-duration generation and grid-edge infrastructure; distributed and behind-the-meter power systems for enterprise AI and edge inference deployments; and strategic acquisitions targeting advanced generation technologies. No transaction timelines or financial terms have been disclosed; additional details are expected through future public disclosure filings.

For the pharma and med-tech operations being divested, the company has indicated it will seek a strategic acquisition partner, though no counterparty or process timeline has been named. The clinical-stage oncology assets remain in play pending that outcome.

The company's ability to close an acquisition partner for its pharma operations while simultaneously standing up an infrastructure platform will serve as the near-term measure of execution against this repositioning.

Source: LIXTE Biotechnology Holdings, Inc. press release via GlobeNewswire, June 1, 2026.